[RESEARCH BLOG] · 2026-09-09
Rapport Therapeutics (RAPP) – Sell Signal Amid Bear Regime and Recent Institutional Activity
By Pierre Brunelle · Founder & Research Lead
Lede: Rapport Therapeutics closed at $46.09 on 2026‑09‑08 (up 0.70%). LOPJLB’s proprietary scanner now flags the stock with a SELL directional signal, a ‑5 score, and a BEAR market‑regime overlay.
Recent News Flow
-
Legal & General Group Plc Acquires Shares of 22,555 Rapport Therapeutics, Inc. $RAPP – The filing, posted on defenseworld.net on 2026‑09‑08, disclosed a fresh purchase of 22,555 RAPP shares, nudging institutional ownership higher and underscoring the insurer’s strategic tilt toward emerging‑stage biotech assets.
-
Deutsche Bank AG Takes $1.34 Million Position in Rapport Therapeutics, Inc. $RAPP – On 2026‑08‑30 the German bank entered the RAPP arena with a $1.34 million stake, framing the purchase as a “tactical exposure to a high‑risk, high‑reward CNS pipeline” and flagging the upcoming Phase II read‑out for RAP‑219 as a potential catalyst.
-
Algert Global LLC Purchases Shares of 223,822 Rapport Therapeutics, Inc. $RAPP – Reported on 2026‑08‑26, the transaction added 223,822 RAPP shares to Algert’s holdings, with commentary emphasizing the “unmet need in bipolar mania” and the differentiated potential of RAP‑219.
-
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP‑219 Clinical Program – On 2026‑08‑24 the company announced a virtual Key‑Opinion‑Leader (KOL) event aimed at psychiatrists and neurologists, where interim safety data and early efficacy signals for RAP‑219 will be presented.
-
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update – The Q2 2026 filing (2026‑08‑05) revealed a widening net loss, continued negative cash flow, and an updated launch horizon that now targets late‑2027, extending the cash‑burn timeline for the $2.33 billion market‑cap firm.
Fundamentals and Valuation
Rapport Therapeutics remains a loss‑making biotech with a trailing twelve‑month (TTM) P/E of –16.02 and an EV/EBITDA of –15.36, both reflecting negative earnings and cash‑flow generation. The balance sheet shows a debt‑to‑equity (D/E) ratio of 2.39, indicating a capital structure weighted toward borrowings—a common trait for clinical‑stage firms that must fund long‑run trial programs.
Margins paint a stark picture of operating distress. Gross margin sits at a perfect 100 %, a statistical artifact of the company’s accounting for research‑related cost of goods sold, while operating margin is ‑767.6 % and net margin ‑685.8 %. These deep negative margins stem from heavy R&D spend, clinical trial outlays, and limited product revenue.
Return metrics are equally sobering. ROIC –17.41 %, ROE –29.02 %, and ROA –29.88 % underscore that capital is not yet being deployed profitably. The price‑to‑book (P/B) ratio of 5.47 suggests the market is pricing the firm well above its book value, a premium justified only by the speculative upside of its CNS pipeline.
Analyst sentiment, however, remains relatively optimistic. The consensus target price is $62.80, representing a ~36 % upside from the current $46.09 level, and the prevailing recommendation is a Buy. This divergence between valuation multiples and analyst optimism reflects the classic biotech “risk‑reward” dichotomy: investors are willing to tolerate current losses in exchange for a potential breakthrough therapy.
Below is a concise snapshot of the most salient valuation metrics:
| Metric | Value |
|---|---|
| P/E (TTM) | –16.02 |
| EV/EBITDA | –15.36 |
| P/B | 5.47 |
| Gross Margin | 100 % |
| Operating Margin | –767.6 % |
| Net Margin | –685.8 % |
| ROE | –29.02 % |
| Analyst Target | $62.80 |
Multi‑Year Financial Trajectory
The company’s earnings per share (EPS) have deteriorated from ‑$0.29 in 2022 to ‑$2.86 in 2025, a more than ten‑fold decline. Free cash flow (FCF) has followed a similar downward path, moving from a modest ‑$3.5 M in 2022 to a staggering ‑$88.1 M in 2025. The price‑to‑earnings ratio has trended less negative as losses have narrowed relative to market cap, moving from ‑39.28 in 2022 to ‑12.79 in 2025, yet the absolute magnitude remains deeply negative.
Return on equity (ROE) spiked to +135.7 % in 2023—a statistical outlier driven by a small equity base and a one‑time accounting adjustment—before settling back into negative territory (‑23 % in 2025). Similarly, return on assets (ROA) has lingered in the ‑20 % to ‑35 % range throughout the period, reflecting the firm’s ongoing asset‑intensive R&D model.
Collectively, the historical data illustrate a company that has yet to achieve commercial scale, with cash burn accelerating as the RAP‑219 program advances through Phase II and toward a pivotal Phase III trial.
ETF Ownership
RAPP’s exposure to exchange‑traded funds remains modest but concentrated among a handful of healthcare‑focused ETFs. The eight largest ETF holders together own roughly 6.5 % of the float, with the top three positions accounting for more than half of that exposure.
The concentration in XPH (a biotech‑focused ETF) and IBRN (a broader healthcare fund) means that any sector‑wide reallocation—whether driven by macro‑level risk aversion or a shift in investor sentiment toward late‑stage pipelines—could exert outsized pressure on RAPP’s share price. Conversely, the presence of these ETFs provides a modest liquidity cushion, as institutional managers must rebalance holdings on a regular schedule.
LOPJLB Signal Read
The LOPJLB scanner currently flags RAPP with a SELL directional signal and a BEAR market‑regime overlay. The composite PERF score of 52.80 and FUND quality score of 5.50 suggest that while the stock’s price momentum is weak, its underlying quality metrics (as defined by the platform’s proprietary algorithm) are modestly above the median for the sector.
The model’s Value score of 3.00, Growth score of 19.00, GARP score of 5.00, and Quality score of 5.50 combine to place RAPP in the Balanced archetype—a blend of growth‑oriented and value‑oriented characteristics. In a bearish regime, the platform’s methodology typically leans toward defensive positioning, which explains the ‑5 directional score and the recommendation to stay on the sidelines until the regime flips or the company delivers a decisive clinical milestone.
Readers are encouraged to explore the interactive chart on the RAPP stock page for a visual overlay of the signal components, and to review the full methodology at the LOPJLB website for a deeper understanding of how the score is derived.
Closing Thoughts & Resources
Rapport Therapeutics sits at a crossroads: a pipeline with high‑risk, high‑reward potential, a balance sheet under pressure from sustained cash burn, and a market environment that is currently unfavorable for speculative biotech plays. The recent institutional purchases from Legal & General, Deutsche Bank, and Algert Global indicate that some capital stewards remain bullish on the long‑run upside, yet the LOPJLB signal framework interprets the present price action and macro backdrop as a sell scenario.
For a complete data set, real‑time charting, and a deeper dive into the signal construction, visit the dedicated stock page: https://www.lopjlb.com/stock/RAPP. Additional earnings‑related commentary (if released) can be found at https://www.lopjlb.com/stock/RAPP/earnings.md, and the broader LOPJLB screener is available at https://www.lopjlb.com/screener.
The information provided herein is for research purposes only and does not constitute investment advice. All investors should conduct their own due diligence and consider their risk tolerance before making any trading decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.